e-learning
resources
2019
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Plasma receptor tyrosine kinase RET in pulmonary arterial hypertension diagnosis and differentiation
Joanna Säleby, Habib Bouzina, Salaheldin Ahmed, Jakob Lundgren, Göran Rådegran
Source:
ERJ Open Res, 5 (4) 00037-2019; 10.1183/23120541.00037-2019
Journal Issue:
October
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Joanna Säleby, Habib Bouzina, Salaheldin Ahmed, Jakob Lundgren, Göran Rådegran. Plasma receptor tyrosine kinase RET in pulmonary arterial hypertension diagnosis and differentiation. ERJ Open Res, 5 (4) 00037-2019; 10.1183/23120541.00037-2019
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The definition of pulmonary hypertension: history, practical implications and current controversies
Pathophysiology of central apnoea: how do we distinguish normal from abnormal?
Should we screen for hereditary pulmonary hypertension?
Related content which might interest you:
Btk (Bruton’s tyrosine kinase) in B cells is overexpressed in patients with idiopathic pulmonary arterial hypertension
Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease
Year: 2015
Pharmacologic characterization of GB002, a novel inhaled PDGFR kinase inhibitor in development for pulmonary arterial hypertension (PAH)
Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension
Year: 2020
Decreased expression of the TGF-beta type I receptor ALK1 in pulmonary arterial hypertension
Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension
Year: 2007
PDGF and Src tyrosine kinases in pulmonary arterial smooth muscle cells: Effects of dasatinib and nilotinib on pulmonary vascular remodeling
Source: Annual Congress 2011 - Treatments for pulmonary hypertension in human and experimental models
Year: 2011
Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors
Source: Eur Respir J, 56 (4) 2000279; 10.1183/13993003.00279-2020
Year: 2020
Targeting bone morphogenic protein receptor 2 (BMPR2) signalling to treat pulmonary arterial hypertension
Source: Eur Respir J, 50 (3) 1701370; 10.1183/13993003.01370-2017
Year: 2017
Src tyrosine kinase is crucial for potassium channel function in human pulmonary arteries
Source: Eur Respir J 2013; 41: 85-95
Year: 2013
Tyrosine kinase inhibition of human pulmonary fibroblast migration
Source: Eur Respir J 2005; 26: Suppl. 49, 101s
Year: 2005
Expression of the MET receptor kinase is a potential functional marker of Idiopathic pulmonary fibrosis
Source: International Congress 2017 – Novel pro- and anti-fibrotic mechanisms in pulmonary fibrosis
Year: 2017
The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis
Source: Eur Respir J 2015; 45: 1426-1433
Year: 2015
Pulmonary complications of tyrosine kinase inhibitors in myeloproliferative disorders
Source: Eur Respir J, 56 (4) 2002653; 10.1183/13993003.02653-2020
Year: 2020
Increased activity of Lyn tyrosine kinase causes multiple chronic obstructive pulmonary disease-like changes in mouse
Source: Annual Congress 2012 - New biomarkers for lung cancer
Year: 2012
Looking to the future: a new decade of pulmonary arterial hypertension therapy
Source: Eur Respir Rev 2011; 20: 262-269
Year: 2011
NMDA receptor activation promotes vascular remodeling and pulmonary arterial hypertension
Source: International Congress 2018 – Pathobiology of pulmonary hypertension
Year: 2018
Genetics of pulmonary hypertension: from bench to bedside
Source: Eur Respir J 2002; 20: 741-749
Year: 2002
Prevention of pulmonary vascular and myocardial remodeling by the combined tyrosine and serine-/threonine kinase inhibitor, sorafenib, in pulmonary hypertension and right heart failure
Source: Annual Congress 2007 - Pathogenesis and novel therapeutic targets in pulmonary hypertension
Year: 2007
Prevention of pulmonary vascular and myocardial remodeling by the combined tyrosine and serine-/threonine kinase inhibitor, sorafenib, in pulmonary hypertension and right heart failure
Source: Eur Respir Rev 2008; 17: 72-73
Year: 2008
Key roles of Src family tyrosine kinases in the integrity of the pulmonary vascular bed
Source: Eur Respir J 2013; 41: 3-4
Year: 2013
Mice deficient in Raf kinase inhibitor protein (RKIP) have elevated indices of pulmonary hypertension
Source: Annual Congress 2010 - Experimental pulmonary hypertension
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept